Resveratrol inhibits rhabdomyosarcoma cell proliferation.
Rhabdomysarcoma is the most common soft tissue tumour in children under the age of 15. Although the introduction of multimodal treatment programmes, including chemotherapy, radiation therapy and excision have increased the overall survival, the chemotherapeutic agents currently used for the treatment of rhabdomyosarcoma exhibit considerable toxicity. The aim of this study was to investigate the effects and possible mechanism(s) of action of resveratrol on human embryonal rhabdomyosarcoma (RD) cells. Resveratrol is a natural polyphenolic compound produced in a number of edible plants and has received considerable attention as a potential chemopreventive and/or chemotherapeutic agent against various types of cancers. In the present study, resveratrol was shown to inhibit cell proliferation of RD cells in a dose-dependent manner with an IC50 of 48.1 micromol/l and induce an arrest in the S/G2 phase of the cell cycle. As evident from immunocytochemical data, resveratrol treatment increased the size of the RD cells. Furthermore, resveratrol treatment resulted in a significant downregulation of cyclin B expression as demonstrated by western blot analyses. In conclusion, the present study shows that resveratrol exerts a strong inhibition of rhabdomyosarcoma cell proliferation in part by arresting cells in S/G2 phase of the cell cycle. These findings warrant further investigation to establish potential use of resveratrol as a relatively non-toxic chemotherapeutic agent for the treatment of rhabdomyosarcoma.
Chow
A W
AW
Department of Surgical Oncology, College of Medicine, College of Pharmacy, University of Illinois at Chicago, 840 South Wood Street (M/C 820), Chicago, IL 60612, USA.
Murillo
G
G
Yu
C
C
van Breemen
R B
RB
Boddie
A W
AW
Pezzuto
J M
JM
Das Gupta
T K
TK
Mehta
R G
RG
D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001707:Biopsy, Needle; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D000077185:Resveratrol; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000473:pathology; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013267:Stilbenes / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects*
D016588:Anticarcinogenic Agents; D013267:Stilbenes; D000077185:Resveratrol